Immunotherapy may replace harsh treatments for some rectal cancers

NCT ID NCT05723562

Ongoing Disease control Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Nov 15, 2025 · Last updated May 14, 2026 · Updated 24 times

Summary

This study tests whether the immunotherapy drug dostarlimab alone can eliminate tumors in people with a specific type of advanced rectal cancer (dMMR/MSI-H) that has not been treated before. About 154 participants will receive the drug and be closely monitored. If the cancer disappears completely and stays gone for at least 12 months, patients can avoid chemotherapy, radiation, and surgery. The goal is to see if this gentler approach is effective enough to become a new standard of care.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

GSK Investigational Site

Los Angeles, California, 90027, United States
GSK Investigational Site

Albuquerque, New Mexico, 87131, United States
GSK Investigational Site

New York, New York, 10022, United States
GSK Investigational Site

Pittsburgh, Pennsylvania, 15232, United States
GSK Investigational Site

Nashville, Tennessee, 37203, United States
GSK Investigational Site

Dallas, Texas, 75390, United States
GSK Investigational Site

Richmond, Virginia, 23298, United States
GSK Investigational Site

Ottawa, Ontario, K1H 8L6, Canada
GSK Investigational Site

Toronto, Ontario, M5G 2M9, Canada
GSK Investigational Site

Montreal, Quebec, H2X 0C1, Canada
GSK Investigational Site

Sherbrooke, Quebec, J1H 5N4, Canada
GSK Investigational Site

Besançon, 25030, France
GSK Investigational Site

Marseille, 13273, France
GSK Investigational Site

Paris, 75012, France
GSK Investigational Site

Pessac, 33604, France
GSK Investigational Site

Rennes, 35000, France
GSK Investigational Site

Berlin, 13353, Germany
GSK Investigational Site

Dresden, 01307, Germany
GSK Investigational Site

Düsseldorf, 40225, Germany
GSK Investigational Site

Frankfurt, 60488, Germany
GSK Investigational Site

München, 81377, Germany
GSK Investigational Site

Milan, 20133, Italy
GSK Investigational Site

Padova, 35128, Italy
GSK Investigational Site

Roma, 00168, Italy
GSK Investigational Site

Chiba, 277-8577, Japan
GSK Investigational Site

Kanagawa, 232-0024, Japan
GSK Investigational Site

Osaka, 540-0006, Japan
GSK Investigational Site

Osaka, 565-0871, Japan
GSK Investigational Site

Utrecht, 3584 CX, Netherlands
GSK Investigational Site

Seoul, 05505, South Korea
GSK Investigational Site

Seoul, 06591, South Korea
GSK Investigational Site

Seoul, 120-752, South Korea
GSK Investigational Site

Seoul, 135-710, South Korea
GSK Investigational Site

Barcelona, 08035, Spain
GSK Investigational Site

Granada, 18014, Spain
GSK Investigational Site

Madrid, 28007, Spain
GSK Investigational Site

Madrid, 28041, Spain
GSK Investigational Site

Santander, 39008, Spain
GSK Investigational Site

Valencia, 46010, Spain
GSK Investigational Site

Leeds West Yorkshire, LS9 7TF, United Kingdom
GSK Investigational Site

London, EC1A 7BE, United Kingdom
GSK Investigational Site

Sutton, SM2 5PT, United Kingdom

Conditions

Explore the condition pages connected to this study.

NEOPLASMS, RECTAL NEOPLASMS, RECTAL